• 1
    Pearson T, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia vera. Lancet 1978;2:12191223.
  • 2
    Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1,213 patients followed for 20 years. Ann Intern Med 1995;123:656664.
  • 3
    Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36(Suppl 1):913.
  • 4
    Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000;79:312318.
  • 5
    Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy—a follow up study of 68 patients. Clin Appl Thromb Hemost 2000;6:3135.
  • 6
    Landolfi R, Ciabattoni G, Patrignani P, Pogliani E, Castellana MAL, Bizzi B, Patrono C. Increased thromboxane A2 biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:19651971.
  • 7
    Landolfi R. Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997;78:617621.
  • 8
    Wieczorek I, MacGregor IR, Ludlam CA. Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol 1995;49:277281.
  • 9
    Wieczorek I, MacGregor IR, Prescott RJ, Ludlam CA. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera. Blood Coagul Fibrinolysis 1992;3:823826.
  • 10
    Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente EA, Leporrier M, Rueff B, et al. Primary myeloproliferative disorder and hepatic vein thrombosis A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. An Intern Med 1985;103:329334.
  • 11
    Wanless IR, Peterson P, Das A, Boinott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathologial study of 145 patients examined at autopsy. Hepatology 1990;12:11661174.
  • 12
    Cardin F, Graffeo M, Mc Cormick PA, Mc Intyre N, Burroughs A. Adult “idiopathic” extrahepatic venous thrombosis. Importance of putative “latent” myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci 1992;37:335339.
  • 13
    Teofili L, De Stefano V, Leone G, Micalizzi P, Iovino MS, Alfano G, Bizzi B. Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost 1992;67:297301.
  • 14
    Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587591.
  • 15
    Mahmoud AEA, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40:798800.
  • 16
    Heresbach D, Pagenault M, Gueret P, et al. Factor V mutation in four patients with small bowel infarction. Gastroenterology 1997;113:322325.
  • 17
    De Stefano V, Chiusolo P, Paciaroni K, Teofili L, Ortu La Barbera E, Casorelli I, Leone G. Hepatic vein thrombosis in a patient with mutant 20210A allele. Thromb Haemost 1998;80:519
  • 18
    Hoffmann R, Nimer A, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: a report of 6 patients. Liver Transpl Surg 1999;5:96100.
  • 19
    Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone JF, Meyer A, Gaub MP, Goetz J, Baumann R, Uring-Lambert B, Levy S, Dufour P, Hauptmann G, Oudet P. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999;116:144148.
  • 20
    Esegel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000;30:6671.
  • 21
    Ergul SM, Rocha Lima CS, Farber JM. Abdominal venous thrombosis with prothrombin gene mutation. Am J Hematol 2000;63:106107.
  • 22
    Marie I, Levesque H, Lecam-Duchez V, et al. Mesenteric venous thrombosis revealing both factor II G20210A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology 2000;118:237238.
  • 23
    Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, Ames PRJ, Marmo R, Mosca S, Balzano A. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001;96:146149.
    Direct Link:
  • 24
    Foulc P, Le Bihan G, Guillerm C, Dorval I, Lellouche F. Portal thrombosis in a patient with Vaquez disease and factor V Leiden. Presse Med 1996;25:1126.
  • 25
    Simsek S, Verheesen RV, Haagsma EB, Lourens J. Subacute Budd-Chiari syndrome associated with polycythemia vera and factor V Leiden mutation. Neth J Med 2000;57:6267.
  • 26
    Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;15:36983703.
  • 27
    Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C[RIGHTWARDS ARROW]T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemost 1997;77:10521054.
  • 28
    Phillips MD. Interrelated risk factors for venous thromboembolism. Circulation 1997;95:19491951.
  • 29
    Rosendaal FR. Venous thrombosis: a multi-causal disease. Lancet 1999;353:11671173.
  • 30
    Janssen HLA, Meinardi JR, Vleggaar FP, van Uum SHM, Haagsma EB, van der Meer FJM, van Hattum J, Chamuleau RAFM, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case control study. Blood 2000;96:23642368.
  • 31
    Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C and protein S levels and activated protein C resistance in polycythaemia vera and essential thrombocythaemia patients with thrombosis. Am J Hematol 1996;52:1420.
  • 32
    Fisher NC, Wilde JT, Roper J, Elias E. Deficiency of natural anticoagulant proteins C, S and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000;46:534539.
  • 33
    Robson SC, Jaskiewicz K, Engelbrecht G, et al. Homeostatic and immunological sequelae of portacaval shunt in rats. Liver 1995;15:293299.
  • 34
    Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol 2000;65:136140.
  • 35
    Gisslinger H, Rodeghiero F, Ruggeri M, Heis-Vahidai Fard N, Mann-halter C, Papagiannopoulos M, Rintelen C, Lalouschek W, Knobl P, Lechner K, Pabinger I. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999;105:551555.
  • 36
    Watson KV, Key N. Vascular complications of essential thrombocythemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198203.